Still watching. The correction in OHRP may interest me more and I'm ~98% invested in the market anyway. There have been a few good comments here lately. Still searching for cause/effect for the recent correction from Jul 3. There wasn't what I regard as major news Jul 3-7. OAK trials/results for NSAIDs, PRP therapy and stem cells were all announced, but I don't see these as immediate threats to AMPE, given trial stages and target patients. But, there may be something I missed, or perhaps there is nothing to miss.
Do you feel OHRP is the better investment at this point? My thoughts are AMPE has more upside in short term, and OHRP can be bought after AMPE rallies hopefully soon. I read the posts on the other board from eyedoc, his comments don't sound very positive. I'm surprised your considering buying more OHRP.
Almost all the smaller bios have been sliding in the last week, I own several. Ampe looks like it's following the same pattern. And Yellen's comments seem to have pushed them down further today. It's frustrating, but when there's no news, these things can get pushed around easily.
Compare the period from June 1st to August 14th, 2013. Then look what happened from August 14 - October 24th. I think we will see the similar patterns.
What is interesting is that Adam Freaudsten wrote a bashing article on June 10, 2013, a few weeks before the SPRING trial positive results announcements. He also wrote a bashing article on June 25th, 2014, a few weeks before the STEP trial announcements. This is stock manipulation before the STEP results announcement. Lot's of money to be made between the peaks and the valleys. Stay long.